(CEL) |
| 0 (0%) 10-15 02:54 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 336.72 |
| Resistance 1: | 288.29 |
| Pivot price: | 279.32 |
| Support 1: | 275.42 |
| Support 2: | 267.46 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 7.450 |
| Book Value | 35.870 |
| PEG Ratio | 2.54 |
| Gross Profit | 26.576 |
| Profit Margin (%) | 12.57 |
| Operating Margin (%) | 18.52 |
| Return on Assets (ttm) | 7.2 |
| Return on Equity (ttm) | 22.0 |
Company news
Wed, 14 Oct 2026
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration - Business Wire
Tue, 13 Oct 2026
How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma? - CancerNetwork
Fri, 09 Oct 2026
Prula-cel Shows Early Promise in Lupus - The Medicine Maker
Wed, 07 Oct 2026
Caribou Biosciences Discontinues Development for Vispa-cel & CB-011 CAR-T Cell Therapy Programs - Pharmaceutical Executive
Wed, 30 Sep 2026
Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial - NeurologyLive
Tue, 29 Sep 2026
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma - OncLive
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
